Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence: A randomized clinical trial

JAMA

Volumn 277, Issue 24, 1997, Pages 1945-1951

  Eissenberg, Thomas ^a,b   Bigelow, George E ^a   Strain, Eric C ^a   Walsh, Sharon L ^a   Brooner, Robert K ^a   Stitzer, Maxine L ^a   Johnson, Rolley E ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c Roxane Laboratories Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVACETYLMETHADOL; METHADONE; OPIATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG URINE LEVEL; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0030916403     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.24.1945     Document Type: Article

References (60)

1. Fulco CE, Liverman CT, Early LE, eds. The Development of Medications for the Treatment of Opiate and Cocaine Addictions: Issues for the Government and Private Sector. Washington, DC: National Academy Press; 1995.
2. Office of National Drug Control Policy. The National Drug Control Strategy: 1996. Washington, DC: Executive Office of the President; 1996.
3. Substance Abuse and Mental Health Services Administration. Preliminary Estimates From the Drug Abuse Warning Network. Washington, DC: US Dept of Health and Human Services; 1996.
4. Goldstein A. Addiction: From Biology to Drug Policy. New York, NY: WH Freeman & Co; 1994.
5. Kreek MJ. Rationale for maintenance pharmacotherapy of opiate dependence. In: O'Brien CP, Jaffe JH, eds. Addictive States. New York, NY: Raven Press; 1992:205-230.
6. Ball J, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York, NY: Springer-Verlag; 1991.
7. Jaffe JH, Schuster CR, Smith BB, Blachly PH. Comparison of acetylmethadol and methadone in the treatment of long-term heroin users: a pilot study. JAMA. 1970;211:1834-1836.
8. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. JAMA. 1965; 193:80-84.
9. Martin WR, Jasinski DR, Haertzen CA, et al. Methadone: a reevaluation. Arch Gen Psychiatry. 1973;28:286-295.
10. Hargreaves WA. Methadone dose and duration for maintenance treatment. In: Cooper JR, Altman F, Brown BS, Czechowicz D, eds. Research on the Treatment of Narcotic Addiction: State of the Art. Washington, DC: US Government Printing Office; 1986:19-79.
11. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose effects of methadone in the treatment of opioid dependence. Ann Intern Med. 1993;119:23-27.
12. Hartel DM, Schoenbaum EE, Selwyn PA, et al. Heroin use during methadone maintenance treatment: the importance of methadone dose and cocaine use. Am J Public Health. 1995;85:83-88.
13. Ling W, Wesson DR, Charuvastra C, Klett JA. Controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry. 1996;53:401-407.
14. Capelhorn JRM, Bell J, Kleinbaum DG, Gebski VJ. Methadone dose and heroin use during maintenance treatment. Addiction. 1993;88:119-124.
15. D'Aunno T, Vaughn TE. Variations in methadone treatment practices: results from a national study. JAMA. 1992;267:253-258.
16. Fraser HF, Isbell H. Actions and addiction liabilities of alpha-acetylmethadols in man. J Pharmacol Exp Ther. 1952;105:458-465.
17. Ling W, Charuvastra C, Kaim SC, Klett CJ. Methadyl acetate and methadone as maintenance treatments for heroin addicts. Arch Gen Psychiatry. 1976;33:709-720.
18. Ling W, Klett JC, Gillis RD. A cooperative clinical study of methadyl acetate, I: three-times-a-week regimen. Arch Gen Psychiatry. 1978;35:345-353.
19. Meinert CL. Clinical Trials: Design, Conduct, and Analysis. New York, NY: Oxford University Press; 1986.
20. Tennant FS, Rawson RA, Pumphrey E, Seecof R. Clinical experiences with 959 opioid dependent patients treated with LAAM. J Subst Abuse. 1986; 3:195-202.
21. Freedman RR, Czertko G. A comparison of thrice weekly LAAM and daily methadone in employed heroin addicts. Drug Alcohol Depend. 1981; 8:215-222.
22. Senay EC, Dorus W, Renault PF. Methadyl acetate and methadone. JAMA. 1977;237:138-142.
23. Savage C, Karp EG, Curran SF, Hanlon TE, McCabe OL. Methadone/LAAM maintenance: a comparison study. Compr Psychiatry. 1976;17:415-424.
24. Jaffe JH, Senay EC, Schuster CR, Renault PE, Smith B, deMenza S. Methadyl acetate vs methadone: a double blind study in heroin users. JAMA. 1972;222:437-442.
25. Zaks A, Fink M, Freedman AM. Levomethadyl in maintenance of opiate dependence. JAMA. 1972; 220:811-813.
26. The LAAM Collaborative Study Group. Levomethadyl acetate (LAAM) for the treatment of opioid dependence: a multisite, open-label study of LAAM safety and an evaluation of the product labeling and treatment regulations. J Maintenance Addict. In press.
27. McGlothlin WH Anglin DA. Long-term followup of clients of high- and low-dose methadone programs. Arch Gen Psychiatry. 1981;38:1055-1063.
28. Kirin TF. Methadone maintenance treatment remains controversial even after 23 years of experience. JAMA. 1988;260:2970-2975.
29. Chaisson RE, Bacchetti P, Osmond D, Brodie B, Sande MA, Moss AR. Cocaine use and HIV infection in intravenous drug users in San Francisco. JAMA. 1989;37:23-28.
30. Kosten TR, Gawin FH, Rounsaville BJ, Kleber HD. Cocaine abuse among opioid addicts: demographic and diagnostic factors in treatment. Am J Drug Alcohol Abuse. 1986;12:1-16.
31. Brooner RK, King VL, Kidorf M, Schmidt CW Jr, Bigelow GE. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997;54:71-80.
32. Woody GC, McLellan AT, Luborsky L, O'Brien CP. Sociopathy and psychotherapy outcome. Arch Gen Psychiatry. 1985;42:1081-1086.
33. Rounsaville BJ, Weissman MM, Kleber H, Wilber C. Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry. 1982; 39:161-166.
34. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750-2755.
35. Cohen J. Statistical Power Analysis for the Behavioral Sciences. Hillsdale, NJ: Lawrence Erlbaum Associates Inc; 1988.
36. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Association; 1987.
37. Methadone Maintenance: Some Treatment Programs Are Not Effective, Greater Federal Oversight Needed. Washington, DC: US General Accounting Office; 1990.
38. Medical Economics Data. Physicians' Desk Reference. Montvale, NJ: Medical Economics Data Production Co; 1996.
39. Spitzer RL, Williams JBW, Gibbon M. Instruction Manual for the Structured Clinical Interview for DSM-III-R. New York, NY: New York State Psychiatric Institute; 1987.
40. Derogatis L. SCL-90-R Manual-II. Towson, Md: Clinical Psychometric Research; 1983.
41. McLellan AT, Luborsky L, Woody GE, O'Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. J Nerv Ment Dis. 1980; 168:26-33.
42. Kosten TR, Rounsaville BJ, Kleber HD. Concurrent validity of the Addiction Severity Index. J Nerv Ment Dis. 1983;171:606-610.
43. National Institute on Drug Abuse. Guide to the Addiction Severity Index: Background, Administration, and Field Test Results. Rockville, Md: National Institute on Drug Abuse; 1985.
44. McLellan AT, Luborsky L, Cacciola J, Evans F, Barr HL, O'Brien CP. New data from the Addiction Severity Index: reliability and validity in three centers. J Nerv Ment Dis. 1985:173;412-423.
45. Babst DV, Chambers CD, Warner A. Patient characteristics associated with retention in a methadone maintenance program. Br J Addict Alcohol Other Drugs. 1971;66:195-204.
46. McLellan AT, Luborsky LK, Woody GE, O'Brien CP, Druley KA. Predicting response to alcohol and drug abuse treatments. Arch Gen Psychiatry. 1983;40:620-625.
47. Hser YI, Anglin MD, Liu Y. A survival analysis of gender and ethnic differences in responsiveness to methadone maintenance treatment. Int J Addict. 1991;25:1295-1315.
48. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Useful predictors of outcome in methadone-treated patients: results from a controlled clinical trial with three doses of methadone. J Maintenance Addict. In press.
49. Pocock SG. Clinical Trial: A Practical Approach. New York, NY: John Wiley & Sons Inc; 1983.
50. Food and Drug Administration. COSTART Second Edition. Rockville, Md: US Dept of Health and Human Services; 1985.
51. Hargreaves WA, Ling W, Brown TC, Weinberg JA, Landsberg R, Harrison WL. Women on LAAM maintenance: initial experiences. J Psychedelic Drug. 1979;11;223-229.
52. Finney DJ. Statistical Method in Biological Assay. New York, NY: Hafner Publishing; 1964.
53. Novick DM, Pascarelli EF, Joseph H, et al. Methadone maintenance patients in general medical practice: a preliminary report. JAMA. 1988;259: 3299-3302.
54. Dole VP. Hazards of process regulations: the example of methadone maintenance. JAMA. 1992; 267:2234-2235.
55. Rettig RA. Yarmolinsky A, eds. Federal Regulation of Methadone Treatment. Washington, DC: National Academy Press; 1995.
56. Cooper JR. Including narcotic addiction treatment in an office-based practice. JAMA. 1995;273: 1619-1620.
57. Magura S, Kang S-Y. Validity of self-reported drug use in high risk populations: a meta-analytical review. Subst Use Misuse. 1996;31:1131-1153.
58. Silverman K, Wong CJ, Higgins ST, et al. Increasing opiate abstinence through voucher-based reinforcement therapy. Drug Alcohol Depend. 1996; 41:157-165.
59. Silverman K, Higgins ST, Brooner RK, et al. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch Gen Psychiatry. 1996;53:409-415.
60. McLellan TA, Arndt IO, Metzger DS, Woody GE, O'Brien CP. The effects of psychosocial services in substance abuse treatment. JAMA. 1993; 269:1953-1959.